Background: IL-17 plays a pathogenic role in asthma. ST2
IL-17-producing ST2
1 group 2 innate lymphoid cells play a pathogenic role in lung inflammation , and aryl hydrocarbon receptor (Ahr) 2/2 mice was examined by using flow cytometry. Bone marrow transfer experiments were performed to evaluate hematopoietic myeloid differentiation primary response gene-88 (MyD88) signaling in regulating IL-17 production by ILC2s. mRNA expression of IL-17 was analyzed in purified naive ILC2s treated with IL-33, leukotrienes, and inhibitors for nuclear factor of activated T cells, p38, c-Jun N-terminal kinase, or nuclear factor k light-chain enhancer of activated B cells. ILC2s. Ahr, but not retinoic acid receptor-related orphan receptor gt, facilitated the production of IL-17 by ILC2 17 s. The hematopoietic compartment of MyD88 signaling is essential for ILC2 17 induction. IL-33 works in synergy with leukotrienes, which signal through nuclear factor of activated T-cell activation to promote IL-17 in ILC2 17 s. Il17 2/2 ILC2s were less pathogenic in lung inflammation. ILC2 17 Key words: Asthma, group 2 innate lymphoid cells, Asthma is one of the most common inflammatory diseases of the airways. The initiation and progression of asthma is driven by various proinflammatory cytokines, which induce recruitment of eosinophils, neutrophils, and macrophages to the airways. The inflammation storm further stimulates lung structural cells, including epithelial cells, to produce chemokines and mucins, which results in tissue remodeling and airway hyperresponsiveness. [1] [2] [3] Type 2 cytokines, typically IL-4, IL-5, and IL-13, have been indicated to be key factors associated with asthma pathology. 3, 4 IL-5 has been shown to be crucial for the development, maturation, and survival of eosinophils. [5] [6] [7] IL-13 induces airway hyperresponsiveness, stimulates chemokine production by epithelial cells, and promotes tissue remodeling. 2, 8, 9 T H 2 cells, one of the T H cell subsets, are well known to be the source for type 2 cytokines. 10 Recently, more and more research has proved that group 2 innate lymphoid cells (ILC2s), a population of innate lymphoid cells, play fundamental roles in type 2 immune responses in patients with antihelminth infections and allergic diseases. [11] [12] [13] [14] [15] [16] [17] The development, maintenance, and expansion of ILC2s are supported by a group of cytokines, including IL-2, IL-7, thymic stromal lymphopoietin, IL-25, and IL-33. 11, 12, [18] [19] [20] Receptors for IL-33 and IL-25 are ST2 and IL-17RB, respectively. IL-33 and IL-25 accumulate 2 distinct populations of ILC2s. [21] [22] [23] 21 Compared with nILC2s, iILC2s produce IL-17 and express higher levels of retinoic acid receptor-related orphan receptor gt (RORgt), which is a master regulator for IL-17 transcription in many types of immune cells. 21, 23 Levels of cysteinyl leukotrienes, which are composed of leukotriene C 4 (LTC 4 ), leukotriene D 4 (LTD 4 ), and leukotriene E 4 , have been found to be increased in different provoked asthmatic responses by promoting chemotaxis of leukocytes and smooth muscle contraction. [24] [25] [26] It has been reported recently that cysteinyl leukotriene receptor 1, the best characterized receptor for cysteinyl leukotrienes, is expressed on ILC2s at a higher level than T H 2 cells and eosinophils. 27, 28 Both LTC 4 and LTD 4 rapidly and potently stimulate production of type 2 cytokines by ILC2s synergistically with IL-33 through the nuclear factor of activated T cells (NFAT) signaling pathway. [27] [28] [29] In addition to IL-5 and IL-13, IL-17 has been indicated to be a pathogenic factor in asthmatic patients. 30 IL-17 can be detected in the lungs, sputum, and bronchoalveolar lavage fluid (BALF) of asthmatic patients. 31, 32 IL-17 levels are associated with disease severity. 32 A previous study identified a population of memory/ effector IL-17
1 T H 2 cells, numbers of which were found to be increased in peripheral blood of patients with atopic asthma. 33 
IL-17
1 T H 2 cells are GATA3 33 One of the mechanisms could be the combinatorial effect of IL-17 and type 2 cytokines in enhancing chemokine production by lung epithelial cells. 33 Another study has shown that exogenous IL-17 exacerbates IL-33-induced asthma by inducing neutrophilic inflammation through CXCR2 signaling. 34 Therefore it is important to investigate the source for IL-17 in the lung and determine molecular regulation of IL-17 production during asthma.
In this study we found that papain or IL-33 treatment boosted IL-17 production from ST2 38 were generated previously. IL-17-deficient mice were kindly provided by Dr Hong Tang (Institute Pasteur of Shanghai, Chinese Academy of Science, Shanghai, China).
All mice used in this study are on a C57BL/6 background and maintained in specific pathogen-free conditions. All mice used in the experiments were 6 to 10 weeks old. Sex-matched male and female mice were used in the study. In the setting of IL-33-induced lung inflammation in which BALF cells were analyzed, littermate female mice were used. All animal experiments were performed in compliance with the ''Guide for the Care and Use of Laboratory Animals'' and approved by the institutional biomedical research ethics committee of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.
Induction of lung inflammation using IL-33 and papain
Mice were injected intraperitoneally with 500 ng of recombinant murine IL-33 (BioLegend, San Diego, Calif) or PBS for 4 consecutive days. In the ''resting'' protocol the IL-33-treated mice were set for 12 days before analysis. In the ''rechallenged'' protocol, rested mice were injected with 500 ng of IL-33 for 2 days before analysis. For the protease allergen papain model, mice were anesthetized with 1% sodium pentobarbital, followed by intranasal administration of papain (30 mg; Calbiochem, San Diego, Calif) in 30 mL of PBS for 3 days in an IL-17 blockade experiment in Rag1 2/2 mice and for 5 days in all other experiments.
Isolation of lung lymphocytes
Lungs were dissected. After fat tissues and bronchus were removed, lungs were cut into pieces and digested in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, Mass) containing DNase I (50 U/mL; Sigma, St Louis, Mo) and collagenase VIII (250 U/mL; Sigma) at 378C for 30 minutes. The digested tissues were homogenized by means of vigorous shaking and passed through a 100-mm cell strainer. Mononuclear cells were then harvested from the interphase of an 80% and 40% Percoll gradient after a spin at 2500 rpm for 20 minutes at room temperature.
Isolation of large intestinal lamina propria lymphocytes
The isolation of large intestinal lamina propria lymphocytes was performed, as previously described. 39 Briefly, the large intestines were dissected, and fat tissues were removed. The intestines were cut open longitudinally and washed in PBS. The intestines were then cut into 3 pieces, washed, and shaken in PBS containing 1 mmol/L dithiothreitol for 10 minutes at room temperature. Intestines were incubated with shaking in PBS containing 30 mmol/L EDTA and 10 mmol/L HEPES at 378C for 10 minutes for 2 cycles. The tissues were then digested in RPMI 1640 medium (Invitrogen, Carlsbad, Calif) containing DNase I (150 mg/mL; Sigma) and collagenase VIII (150 U/ mL; Sigma) at 378C in a 5% CO 2 incubator for 1.5 hours. The digested tissues (Fig 1, A-I ) or Rag1 2/2 (Fig 1, J-N) mice. Lung lymphocytes were isolated for analysis. Fig 1, A, Cells were cultured in medium for 48 hours, and supernatants were collected. IL-17 levels were measured by using ELISA, and the amount of IL-17 normalized to tissue weight was shown. Fig 1, B , mRNA expression of IL-17 in lung lymphocytes was analyzed by using real-time RT-PCR. Fig 1, C and J, Expression of lineage markers (Lin) and IL-17 gated on live lymphocytes from indicated groups was analyzed by using flow cytometry. Fig 1, D (Fig 1, I ) from the lungs of individual mice are shown. Data are means 6 SEMs. Fig 1, F and M, Expression of GATA3 and IL-17 gated on Lin 2 cells was analyzed by using flow cytometry. Fig 1, G were homogenized by means of vigorous shaking and passed through a 100-mm cell strainer. Mononuclear cells were then harvested from the interphase of an 80% and 40% Percoll gradient after a spin at 2500 rpm for 20 minutes at room temperature.
Flow cytometry
Anti-mouse CD16/32 antibody was used to block nonspecific binding to Fc receptors before all surface staining. Antibodies used for regular flow cytometry were purchased from Thermo Fisher Scientific (eBioscience), except for anti-GATA3 (BD Biosciences, San Jose, Calif), anti-Siglec-F (BD Biosciences), and anti-ST2 (MD Biosciences, Oakdale, Minn) antibodies. For nuclear staining, cells were fixed and permeabilized with a Mouse Regulatory T Cell Staining Kit (Thermo Fisher Scientific). Antibodies used for 11-color flow cytometry were purchased from BD Biosciences.
For cytokine staining, cells were stimulated with phorbol 12-myristate 13-acetate (50 ng/mL; Sigma) and ionomycin (500 ng/mL; Sigma) for 4 hours. Brefeldin A (2 mg/mL; Sigma) was added for the last 2 hours before cells were harvested for analysis. Dead cells were stained with the Live and Dead Violet Viability Kit (Invitrogen) and gated out in analysis.
Flow cytometric data were collected by using the Gallios flow cytometer Fig E1; and Fig  E2, B-E, were CD3, B220, CD11b, CD11c, Gr-1, NK1.1, and FcεRI, respectively. Linage markers were CD3, B220, CD11b, and CD11c for other figures, unless otherwise described.
In vitro ILC2 culture
In vitro culturing of ILC2s was performed according to the methods of a previous study. 27 Lin 2 ST2 1 CD25 1 ILC2s were purified from the lungs and In vivo treatment with CsA or FK506
Mice were treated subcutaneously with 50 mL of CsA (80 mg/kg) or FK506 (8 mg/kg), which was dissolved in a mixture of 50% dimethyl sulfoxide and 50% olive oil, daily for 7 days before IL-33 treatment and also during IL-33 treatment. For IL-33 treatment, mice were intraperitoneally injected with 500 ng of IL-33 daily for 4 consecutive days.
Detection of LTC 4 and IL-17 by means of ELISA
For measurement of LTC 4 levels, lung tissues were homogenized in 1 mL of PBS. The extract was centrifuged, and LTC 4 levels in supernatants were measured by using the LTC4 ELISA Kit (Cayman Chemical), according to the protocol provided by the manufacturer.
Mouse IL-17A ELISA was developed by using a capture antibody (eBio17CK15A5; Thermo Fisher Scientific) and detection antibody (eBio17B7; Thermo Fisher Scientific). Absorbance at a wavelength of 450 nm was analyzed with a spectrophotometer (BioTek, Winooski, Vt). 
Bone marrow transplantation

In vivo blockade of IL-17 or IL-25
Female mice were treated intraperitoneally with 500 ng of IL-33 for 4 consecutive days or intranasally with 30 mg of papain for 3 days to induce lung inflammation. Mice were killed for analysis 24 ) from the lung and colon were sorted by using flow cytometry (purity > 98%). Rag2
Induction of lung inflammation in
2/2
Il2rg
2/2 mice were injected intravenously with 2 3 10 5 ILC2s purified from wild-type or Il17 2/2 mice and treated subsequently intraperitoneally with 500 ng of IL-33 on 4 consecutive days.
Analysis of BALF
Mice were killed, and a gavage needle connected to a 1-mL syringe containing 1 mL of cold PBS was inserted into the exposed trachea. PBS was injected, aspirated back into the syringe, and set aside on ice. The process was repeated once. BALF was then centrifuged at 4602 relative centrifugal force for 3 minutes. Cells were resuspended in 100 mL of PBS. A 5-mL aliquot of BALF was used for determination of total cell numbers, and the rest was used for flow cytometric analysis.
Histologic analyses
Tissues from the left lungs of mice were dissected and immediately fixed with 4% paraformaldehyde. Tissues were then embedded in paraffin and sectioned longitudinally at 7 mm. Sections were then processed for periodic acid-Schiff (PAS) staining to evaluate mucin production with a light microscope (Zeiss, Oberkochen, Germany). Numbers of PAS 1 bronchiole/ bronchus structures on each section were quantified. Percentages of PAS 1 bronchiole/bronchus structures among total bronchiole/bronchus structures were calculated. The PAS 1 area in each analyzed bronchiole/bronchus structure was analyzed with ImageJ software (National Institutes of Health, Bethesda, Md). In addition, percentages of PAS 1 area in total area of each analyzed bronchiole/bronchus structure were calculated. All the PAS 1 bronchiole/bronchus structures on the sections were analyzed to determine an average percentage of PAS 1 area per bronchiole/bronchus structure.
Measurement of airway responsiveness to methacholine
ILC2s were purified from IL-33-treated wild-type or Il17 2/2 mice and expanded in vitro with IL-7 (10 ng/mL) and IL-33 (10 ng/mL) for 7 days. Rag2
Il2rg 2/2 mice were injected intravenously with 2 3 10 5 wild-type or Il17 2/2 ILC2s. Lung inflammation was then induced by 3 injections of 500 ng of IL-33 daily and 1 injection of 30 mg of papain administered intranasally.
Methacholine challenge was performed 24 hours after the last injection of papain. Lung resistance was measured through a computer-controlled FinePointe RC system (Buxco Electronics, Wilmington, NC), as described are representative of at least 2 independent experiments. Wt, Wild-type. *P < .05, **P < .01, and ***P < .001. previously. 40 Briefly, mice were anesthetized with 60 mg/kg pentobarbital administered intraperitoneally, and the trachea was cannulated with an 18-gauge metal needle connected to the RC system. Mice were ventilated mechanically at a frequency of 140 breaths/min with a tidal volume of 0.2 mL. Aerosolized methacholine was administered in 30 seconds in increasing concentrations (6.25, 12.5, and 25 mg/mL methacholine). Lung resistance was continuously computed by fitting flow, volume, and pressure to an equation of motion.
Detection of mRNA by using real-time RT-PCR RNA was isolated with TRIzol reagent (Thermo Fisher Scientific). cDNA was synthesized with the GoScript Reverse Transcription Kit (Promega, Madison, Wis). Real-time PCR was performed with FastStart Universal SYBR Green Master (Roche Mannheim, Germany). Reactions were run with QuantStudio 7 software (Thermo Fisher Scientific). The results were displayed as relative expression values normalized to b-actin. Primers used in this study are shown in Table E1 ical sample was pooled from 2 to 3 mice. RNA was extracted, and expression of ILC2 signature genes was analyzed by using real-time RT-PCR. Relative expression of genes was analyzed by means of normalization to b-actin. Genes consistently differentially expressed at greater than 1.5-fold were confirmed with another 2 biological repeats by using real-time RT-PCR.
Statistical methods
Unless otherwise noted, statistical analysis was performed with the unpaired Mann Whitney U test on individual biological samples by using GraphPad Prism 5.0 software (GraphPad Software, La Jolla, Calif). Data from such experiments are presented as means 6 SEMs. A P value of less than .05 was considered statistically significant.
RESULTS
IL-33 induces IL-17-producing ILC2s independently of the adaptive immune system
When mice were treated with IL-33 in vivo, we observed increased IL-17 production from lymphocytes in the lung (Fig  1, A) . Consistently, mRNA expression of IL-17 in lung lymphocytes was significantly greater in IL-33-treated mice than in control mice (Fig 1, B) . Using flow cytometric analysis, we found the majority of IL-17 was produced from Lin 2 cells (Fig 1, C) . Both percentages and cell numbers of Lin 2 IL-17 1 cells were increased on IL-33 treatment (Fig 1, D and E 
GATA3
1 cells (Fig 1, F) 
1 IL-17 1 cells are indeed ILC2s. Notably, ILC2s produced a limited amount of IL-17 under steady-state conditions but acquired the ability to produce significantly greater amounts of IL-17 after challenge with IL-33 (Fig 1, F and G) .
The above data suggest that IL-33 promotes IL-17 production from ILC2s, which are the major source for IL-17 among lung lymphocytes after IL-33 injection. In the setting of papaininduced lung inflammation, we also observed induction of IL-17 expression from ILC2s (Fig 1, H and I ), although to a lesser degree compared with that in IL-33-injected mice (Fig 1, G) .
To determine whether induction of IL-17-producing ILC2s by IL-33 is dependent on the adaptive immune system, we injected IL-33 into Rag1 2/2 mice. Similarly, we observed increased percentages and total cell numbers of Lin 
IL-17
1 cells was found (Fig 1, K) . In addition, IL-17 was produced mainly by Lin 2
GATA3
1 ILC2s on IL-33 injection (Fig 1, M) . IL-17 production gated on ILC2s from IL-33-injected mice was increased significantly compared with that in the PBS-treated group, which had barely any IL-17
1 ILC2s (Fig 1, M and N) . The above data suggest that IL-33 enhances IL-17 production from ILC2s independently of the adaptive immune system.
In addition to the lung, systemic administration of IL-33 to mice induced IL-17 production from Lin 2 cells in the large intestine but not in bone marrow or the mesenteric lymph nodes, despite an expansion of ST2 1 ILC2s in all analyzed organs (see Fig E1, A-C, in this article's Online Repository at www. jacionline.org). IL-17 production within ILC2s in the large intestine showed a trend for enhancement in wild-type mice, and this was significant in Rag1 2/2 mice, although to a smaller extent than in the lung (Fig 1, N, and see Fig E 1, D-F) . Therefore we focused on the biology of IL-33-induced IL-17 1 ILC2s in the lung. The above data imply a tissue-specific feature for induction of IL-17
1 ILC2s by IL-33.
Induction of IL-17-producing ST2
1 ILC2s is independent of RORgt RORgt has been known as a master regulator for IL-17 expression in various types of immune cells. [43] [44] [45] In addition,
representative of 2 independent experiments. D and E, ILC2s were purified from naive wild-type mice and cultured with IL-7 for 24 hours. Cells were then treated with or without IL-33 for 24 hours. In some groups LTC 4 (100 nmol/L) or LTD 4 (100 nmol/L) was added for the last 4 hours before cells were collected for analysis. independent experiments. *P < .05, **P < .01, and ***P < .001. 
ST2
1 cells (see Fig E4, A and B) . In addition, neither ST2
1 IL-17 1 nor ST2 2 IL-17 1 driven by IL-33 expressed RORgt (see Fig E4, C and D) . We also confirmed that in the setting of papain-induced lung inflammation, IL-17 expression was induced in ST2
1 ILC2s but not ST2 2 ILC2s (see Fig E4,  E and F) .
To further determine whether RORgt was required for induction of ST2 (Fig 2, A and B) . (Fig 2, C and D) . The IL-17 1 ILC2s in Ahr 1/2 and Ahr 2/2 mice were ST2 1 (see Fig E4, H) . This suggests that Ahr facilitates the induction of ILC2 17 s by IL-33. The percentage of ILC2s in the lung, as well as IL-5 production by ILC2s, was comparable between Ahr 2/2 mice and the control group (Fig  2, E-G) , indicating that Ahr has no effect on expansion of ILC2s or expression of type 2 cytokines by ILC2s in response to IL-33. The reliance on IL-17, but not IL-5, production by ILC2s on Ahr was similarly observed in papain-induced lung inflammation (Fig 2, H and I) .
We then investigated whether Ahr regulated IL-17 production from ST2
1 ILC2s in the absence of other immune or nonimmune cells. We purified ST2
1 ILC2s from naive Rag1
Ahr 2/2 mice or Rag1 2/2 mice and treated the cells with IL-7 and IL-33 in vitro. In this culture system we avoided the effect of non-ILC2s, which might indirectly affect IL-17 production from ILC2s. After 7 days of culture, IL-17 was readily detectable from ILC2s in the control group (Fig 2, J) . Notably, IL-17 expression from Ahr-deficient ILC2s was significantly less than that in the control group (Fig 2, J and K) . Nevertheless, Ahr-deficient ILC2s exhibited no defective IL-5 expression compared with control ILC2s (Fig 2, J and L) . ILC2s maintained ST2 expression during in vitro expansion (Fig 2, M) . The above data indicate that Ahr regulates induction of ILC2 17 s by IL-33 independently of other cell types.
MyD88 signaling from the hematopoietic compartment is essential for ILC2 17 induction
MyD88 signaling has been known as the key molecule mediating downstream signals of IL-33. 50 We used MyD88-deficient mouse to perform bone marrow transfer experiments to determine whether the hematopoietic or nonhematopoietic system was essential for ILC2 17 induction by IL-33.
Under steady-state conditions, IL-17 production from ILC2s was comparably low in wild-type and MyD88-deficient mice gated on ILC2s of donor origin (Fig 4, A and B) . After IL-33 treatment, ILC2s from MyD88-deficient donors exhibited defective induction of IL-17 compared with ILC2s from wild-type donors (Fig 4, A and B) , suggesting MyD88 signaling from the hematopoietic cells is essential for ILC2 17 induction in the lung. In contrast, expression of IL-17 from wild-type ILC2 donor cells was similarly induced by IL-33 in wild-type and MyD88-deficient recipients (Fig 4, C and D) , suggesting MyD88 signaling from nonhematopoietic cells is dispensable for induction of ILC2 17 s in the lung by IL-33.
Sustained IL-33 signal is essential for maintenance of ILC2 17 s IL-33-challenged ILC2s have been reported to be sustained in the lung for up to 60 days without continuous supplementation of endogenous or exogenous IL-33. 51 Therefore we questioned whether ILC2 17 s would be retained in the lung after we stopped IL-33 treatment for a period of time.
We designed a ''resting'' protocol in which we injected wildtype mice with IL-33 for 4 consecutive days and analyzed cytokine production from ILC2s 12 days later. We found the percentage of IL-17 expression from ILC2s significantly decreased in rested mice compared with mice freshly challenged with IL-33 (see Fig E5, A and B, in this article's Online Repository at www.jacionline.org). In addition, induction of IL-17 from ILC2s could be achieved again when we rechallenged rested mice with IL-33 (see Fig E5, A and B) . The above data suggest continuous IL-33 signal is required for maintenance of ILC2 17 s.
Leukotrienes and IL-33 synergistically induce mRNA expression of IL-17 in ILC2s
The reliance of ILC2 17 s on IL-33 signaling led us to question whether IL-33 could directly drive mRNA expression of IL-17 in ILC2s. To test this, we purified ILC2s from naive wild-type mice and stimulated them with or without IL-33 in vitro in the presence of IL-7 to maintain the survival of ILC2s. Intriguingly, although IL-33 efficiently induced mRNA expression of IL-13 (Fig 3, A) , no enhancement of IL-17 mRNA expression in ILC2s was observed with either short-term (24 hours) or long-term (72 hours) stimulation with IL-33 (Fig 3, B) . This suggests that IL-33 alone does not induce mRNA expression of IL-17 in ILC2s.
Leukotrienes have been shown to stimulate type 2 cytokine production by ILC2s through inducing calcium influx and activating NFAT. 27 Thus we determined whether leukotrienes could induce mRNA expression of IL-17 in ILC2s. Consistently, LTC 4 could be detected in lung tissues of both wild-type and Rag1 2/2 mice, although injection of IL-33 did not significantly alter LTC 4 levels (Fig 3, C) .
We found both LTC 4 and LTD 4 efficiently enhanced mRNA levels of IL-13 in ILC2s purified from naive mice, which was consistent with previous reports (Fig 3, D) . Surprisingly, no induction of IL-17 mRNA was observed with LTC 4 or LTD 4 treatment (Fig 3, E) , suggesting leukotriene alone does not drive the mRNA expression of IL-17 in ILC2s. However, in the presence of IL-33, both LTC 4 and LTD 4 greatly enhanced mRNA levels of IL-17 in ILC2s (Fig 3, E) more than 100-fold compared with IL-33 alone or leukotriene alone (Fig 3, E) . This synergistic effect of leukotrienes and IL-33 was also obvious for the induction of IL-13 mRNA expression in ILC2s (Fig 3, D) . Nevertheless, the combinatorial effect of the two to induce IL-13 production by ILC2s was not so striking compared with IL-33 alone, which is already a strong inducer of IL-13 expression (Fig 3, D) . However, both leukotrienes and IL-33 are essentially required for induction of IL-17 mRNA expression in ST2 1 ILC2s. Cysteinyl leukotriene receptor 1 has been reported to signal through NFAT and protein kinase C. 27, 52 In addition, IL-33 activates multiple proinflammatory cascades, including mitogen-activated protein kinase and NF-kB. 53 We then treated ILC2s with inhibitors for key signaling molecules in the presence of LTC 4 and IL-33. We found CsA, an inhibitor of NFAT signaling, dramatically abolished induction of IL-17 in ILC2s (Fig 3, F) . CsA also significantly inhibited mRNA expression of IL-13 in ILC2s, although to a lesser degree compared with the inhibitory effect on IL-17, which is consistent with a milder effect of leukotrienes to boost IL-13 in the presence of abundant IL-33 (Fig 3, F) . Similarly, in vivo blockade of NFAT signaling with CsA or FK506 profoundly diminished induction of ILC2 17 s, whereas IL-13 expression by ILC2s was affected at a lesser extent (Fig 3, G-I) . 54 Inhibitors for p38 and JNK suppressed mRNA expression of both IL-17 and IL-13 in a dose-dependent manner (Fig 3, F) . Although inhibitor for NF-kB slightly but significantly inhibited IL-17 expression in ILC2s, it had no effect 
GATA3
1 cells (ILC2s; Fig 4, A) or Thy1.1 1 ILC2s (Fig 4, C) of donor origin was analyzed by using flow cytometry. B and D, Percentages of IL-17 gated on ILC2s of donor origin were shown. Data are presented as means 6 SEMs and representative of 3 independent experiments. SSC, Side scatter; WT, wild-type. *P < .05 and **P < .01.
J ALLERGY CLIN IMMUNOL VOLUME 143, NUMBER 1 on expression of IL-13 at the same dose (Fig 3, F) . The above data suggest NFAT signaling is essential for induction of ILC2 17 s. In addition, multiple signaling cascades downstream of IL-33, including NF-kB, JNK, and p38, are collectively supportive of IL-17 mRNA expression in ILC2s.
ILC2 17 s play a pathogenic role in IL-33-induced lung inflammation
Our finding suggests ILC2s expanded by IL-33 serve as an endogenous source of IL-17. Thus we evaluated the pathogenicity of ILC2 17 s in IL-33-induced lung inflammation in Rag1 2/2 mice, in which we could limit the role of IL-33 more stringently to ILC2s. We found depletion of IL-17 by neutralization antibody significantly reduced the percentage and cell number of neutrophils in the BALF (Fig 5, A-C) . Percentages and cell numbers of eosinophils in BALF showed a trend for downregulation after depletion of IL-17, but the change was not significant compared with that in the IgG-treated group (Fig 5, A-C) . We then evaluated mucin production in lung epithelial cells using PAS staining. Although no difference was found in the percentage of PAS 1 area at a per-bronchus/bronchiole level (Fig 5, D and E) , numbers of PAS 1 bronchi/bronchioles were significantly lower in IL-17-depleted mice than in the IgG group among IL-33-treated mice (Fig 5, D and F) . This suggests mucin-producing lung epithelial cells are less disseminated in IL-17-depleted mice than control mice after IL-33 treatment, indicating a restriction of the pathology after IL-17 neutralization. Notably, blockade of IL-17 in Rag1 2/2 mice similarly prohibited the infiltration of neutrophils and eosinophils to the airways in papain-induced lung inflammation (Fig 5, G-H) . Therefore we conclude endogenous IL-17 plays a pathogenic role in lung inflammation by promoting recruitment of inflammatory cells to the airways and enhancing mucus production by lung epithelial cells.
Although ILC2s are locally the dominant cell population that secretes IL-17 in the setting of IL-33-induced lung inflammation, it is possible that systemic IL-17 derived from group 3 innate lymphoid cells and neutrophils plays a role in the disease. 55 Therefore we induced disease and neutralized IL-17 in Rag1 Rorc gfp/gfp mice, as indicated by reduced percentages and cell numbers of neutrophils in BALF, although percentages and cell numbers of BALF eosinophils were not affected (see Fig E6) . The above data indicate that IL-33-induced IL-17 exacerbates lung inflammation independently of RORgt, implying a critical role for ILC2-derived IL-17 in the disease.
To further elaborate the pathogenic role of ILC2 17 s, we adoptively transferred IL-33-expanded ILC2s purified from IL-17-deficient mice or wild-type mice to Rag2
Il2rg
2/2 mice, which lacked innate lymphoid cells. We then induced lung inflammation in Rag2 2/2 Il2rg 2/2 mice by injecting IL-33 (Fig 6, A) . ILC2s from Il17 2/2 and wild-type mice expanded equally in Rag2
Il2rg 2/2 mice after IL-33 treatment (Fig 6, B) . In addition, Il17 2/2 ILC2s had no defective IL-5 or IL-13 production compared with wild-type mice (Fig 6, C) . In addition, lymphocytes isolated from IL-33-treated Rag2
2/2
Il2rg
2/2 mice receiving Il17 2/2 ILC2s had barely detectable IL-17 production compared with that seen in mice receiving wild-type ILC2s (Fig 6, D) , further indicating ILC2s as the major source for IL-17 in this disease. Consistently, we observed significant reduction in percentages and total cell numbers of both neutrophils and eosinophils in the BALF of Rag2
2/2 mice receiving Il17 2/2 ILC2s compared with mice transferred with wild-type ILC2s (Fig 6, E-G) . The above data suggest Il17 2/2 ILC2s are less potent in recruiting inflammatory cells to the airways. Strikingly, in the setting of lung inflammation induced with IL-33 together with intranasal administration of papain, airway hyperresponsiveness was significantly lower in Rag2 2/2 Il2rg 2/2 mice transferred with Il17 2/2 ILC2s than wild-type ILC2s (Fig 6, H) . This supports the notion that ILC2 17 s are highly pathogenic in the setting of lung inflammation. (Fig 7, A) . Thus the ILC2 17 s phenotypically mirror the previously described IL-17 Table E1 ). 56 Although the majority of ILC2 signature genes were expressed at similar levels between ILC2 17 s and IL-17 2 ILC2s, including ST2, GATA3, and IL-13 (see Fig E2, A, in this article's Online Repository at www.jacionline.org), 15 genes were found to be differentially expressed by ILC2 17 s than IL-17 2 ILC2s by greater than 1.5-fold (Fig 7, B , and see Table E2 in this article's Online Repository at www.jacionline.org). Although IL-17RB was expressed at a higher level in IL-17
1 ILC2s compared with IL-17 2 ILC2s, blockade of IL-25 with neutralizing antibody or genetic ablation of IL-25 in mice did not impair induction of ILC2 17 s (Fig 1, G, and see Fig E2, B-E) . This suggests IL-33 induces ILC2 17 s through an IL-25-independent mechanism.
Notably, the mRNA expression of GM-CSF was significantly lower in ILC2 17 s than IL-17 2 ILC2s (Fig 7, B and C) . Because GM-CSF production by ILC2s has been well established and GM-CSF plays an essential role in lung inflammation, 11, 57, 58 we analyzed expression of GM-CSF at the protein level in ILC2 17 s by using flow cytometry (Fig 7, D) . Surprisingly, in the lungs of IL-33-treated wild-type or Rag1 2/2 mice, both ILC2 17 s and IL-17 2 ILC2s expressed a limited amount of GM-CSF (Fig 7, D and E) . Slightly more GM-CSF was derived from IL-17
2 ILC2s compared with ILC2 17 s, which is consistent with a lower level of Csf2 mRNA in ILC2 17 s (Fig 7, D) . Intriguingly, we found GM-CSF expression in naive and rested ILC2s (as described in Fig E5) , predominantly by IL-17 2 ILC2s, was significantly greater than the expression in IL-33-challenged ILC2s (Fig 7, D and E) . Therefore IL-33 treatment results in different kinetics of GM-CSF and IL-17 production by ILC2s. ILC2s (upper left quadrant in Fig 7, D) in ILC2s from the indicated groups are shown. Data are means 6 SEMs. Fig 7, A to E, Data are representative of 2 independent experiments. SSC, Side scatter; Wt, wild-type. *P < .05 and **P < .01.
J ALLERGY CLIN IMMUNOL VOLUME 143, NUMBER 1 DISCUSSION IL-17 has been known to play an important role in the pathogenesis and progression of asthma. 30 Increased IL-17 levels in the lungs of asthmatic patients have been associated with severe and heterogeneous forms of the diseases. 32, 59 A previous study has shown that memory/effector IL-17
1 T H 2 cells are more pathogenic in asthmatic patients than classical T H 2 and T H 17 cells in terms of recruiting leukocyte infiltration to the airways and promoting mucin production by lung epithelial cells. 33 In this study we identified papain or IL-33-induced ST2 21 In contrast, ILC2 17 s did not express RORgt, and their production of IL-17 was independent of RORgt. Consistently, the severity of IL-33-induced lung inflammation was comparable in RORgt-deficient mice compared with control mice, suggesting that RORgt was dispensable for the pathogenicity of ILC2 17 s.
Ahr has been shown to regulate the expression of T H 17 cytokines in various immune cells. 46, 49, 60 We found Ahr-deficient mice had defective induction of ILC2 17 s compared with littermate control mice, with no defect in expansion of ILC2s by IL-33 or production of type 2 cytokines. In vitro culturing of ILC2s from naive Ahr-deficient mice with IL-33 showed reduced expression of IL-17, indicating that Ahr facilitates induction of ILC2 17 s in an ''ILC2-only'' system. Furthermore, we have shown that induction of IL-17 mRNA expression requires a cooperative effect of IL-33 and leukotrienes, the receptor of which is highly expressed by ILC2s. 27 Accumulation of IL-17 mRNA in IL-33-treated lung lymphocytes is likely due to a combinatorial effect on ILC2s by IL-33 and leukotrienes, which could be detected in lung tissue.
The synergistic effect of IL-33 and leukotrienes in promoting type 2 cytokines has been proved in a previous study. 27 Here we show that leukotrienes and IL-33 work together to induce mRNA expression of IL-17. Importantly, we found leukotriene or IL-33 alone was not potent enough to induce IL-17 expression, whereas IL-13 induction could be achieved with each of them. Considering IL-17 is typically not a signature cytokine for ILC2s, we reasoned the induction of IL-17 expression required multiple factors. Consistently, both NFAT downstream of leukotriene signaling and NF-kB/p38/JNK downstream of IL-33 signaling were important for IL-17 expression by ILC2 17 s. In contrast, expression of IL-13 by ILC2s was less dependent on NFAT than expression of IL-17. Therefore, when there is abundant IL-33, further promotion of type 2 cytokine production by leukotrienes might be mild. In contrast, expression of IL-17 by ILC2s is highly sensitive to the presence of leukotrienes. This finding broadens our understanding on the pathogenicity of leukotrienes in asthmatic patients by promoting ILC2 17 It is intriguing that ILC2 17 s express little GM-CSF, an ILC2 signature cytokine that plays an important role in lung inflammation. 11, 57, 58 In fact, we found ILC2s produced decent levels of GM-CSF under steady-state conditions. However, GM-CSF production in ILC2s was reduced on IL-33 injection and recovered after withdrawing IL-33, which was opposite to the kinetics of IL-17 expression by ILC2s in response to IL-33. The above data indicate that IL-33 plays an inhibitory role in GM-CSF production by ILC2s. Considering ILC2s can be maintained in vivo for a long time independently of IL-33, IL-17 and GM-CSF could in turn participate in progression of lung inflammation after an initial challenge with IL-33. Significance of the opposite effect of IL-33 on GM-CSF and IL-17 production by ILC2s needs to be investigated further in animal models and clinical studies. Together, our finding highlights the pathogenicity of ILC2 17 
